1. Resistant Infectious Disease Technologies
The University of Chicago
Available for download at
tech.uchicago.edu/areas

2. UChicago’s Unique Infectious Disease Capabilities
UChicago’s unique access to infectious disease facilities, clinical research centers, and world-renowned
leaders in the fight against pathogens ensures maximum investment return for industry collaborators.
MRSA Research Center
Howard T. Ricketts Laboratory (HTRL)
• UChicago’s HTRL located at Argonne National Laboratory is one of
13 regional BSL-3 facilities in the US
• HTRL mission is the creation of novel
therapeutics for biodefense and emerging
infectious diseases.
Great Lakes Regional Center of Excellence (GLRCE)
• MRSA Research Center is a consortium of 20 members at
UChicago who collaborate on studying the spread and
progression of MRSA disease
• Center’s MRSA strain bank receives patient-derived MRSA
strains daily from the UChicago Medical Center, stores them
and warehouses molecular/clinical info from these isolates
• Info used for resistant-resilient
antibiotic and vaccine efforts
• GLRCE combines the research excellence of inter-disciplinary
scientists at 27 member institutions in the Great Lakes region
• Biodefense & emerging disease vaccine/therapeutic focus
• Administered by UChicago
Olaf Schneewind, MD, PhD
• Olaf Schneewind is the director of the GLRCE for Biodefense
and Emerging Infectious Diseases Research
• Dr. Schneewind is a pioneer in using a reverse vaccinology
approach to identify key antigens for vaccines that have been
show to confer protective immunity in mouse models
• “This finding represents a promising step toward identifying
potential components to combine into a vaccine designed for
people at high risk of invasive S. aureus infection,”
Anthony S. Fauci, M.D., NIAID director (NIH News)
Robert Daum, MD
• Robert Daum is the director of the MRSA Research Center and
has been at the forefront of the discovery and raising the
alarm about community-acquired MRSA
• A Nature news feature “Man vs. MRSA” highlights Dr. Daum’s
efforts and the groundbreaking work being done at UChicago
on attacking resistance mechanisms
•
http://www.nature.com/news/vaccine-development-man-vs-mrsa-1.9940

3. UChicago’s Multi-front Assault on Infectious Diseases
World-class labs focused on MRSA eradication, along with a marriage of biochemical and clinical
expertise, have lead to a range of technologies targeted to some of the deadliest pathogens.
Antibody-based therapeutics and vaccines
Resistance-Evading Small Molecule
Anti-Infectives
MRSA
MRSA
MRSA
X
ADAM10
S. aureus (MRSA)
MRSA
S. pneumoniae
Gram positives
Anthrax/Bioweapons
Toxoplasma
Flu
Platform Technologies
Subunit and Live Vaccines
-Peptide Vaccine/Adjuvant Platform
-Microbiome-Disease Platform

4. Resistance-evading small molecule anti-infectives
New therapeutics have little value if
pathogens rapidly acquire resistance.
UChicago’s in-development small
molecule anti-infectives avoid
resistance by directly targeting
resistance pathways, host functions, or
conserved and essential cell surface
proteins.
Without anti-infective
With anti-infective
MRSA
MRSA
ADAM10
ADAM10
X
ADAM10
Epithelial
permeability
Representative Technologies
Robert Daum, MD
• New antibiotics and small molecule potentiators
of antibiotic sensitivity for overcoming resistance
to therapy in patients with MRSA
• S. aureus vaccine development
Julie Bubeck Wardenburg, MD, PhD
• Topically administered small molecule inhibitor of
ADAM10, a host cell surface receptor, for the
treatment of S. aureus- and S. pneumonia–
mediated pneumonia and skin and soft tissue
infections (SSTIs)
Dominique Missiakas, PhD
• Broad-spectrum Gram-positive small molecule
antibiotic: lipoteichoic acid synthase (LtaS)
inhibitor targets a critical cell wall component
• Demonstrated robustness against the
development of resistance in laboratory screens

5. Antibody therapeutics and vaccines
UChicago antibodies directly target the
repertoire of pathogen immune-evasion
mechanisms that have undermined
staphylococcal and influenza vaccines in the
past. UChicago labs lead in the study of
antigens critical to these pathways and in
the development of protective antibody
binders of these antigens.
MRSA
MRSA
Mutated antigen restores effective antibody response
Representative Technologies
Olaf Schneewind, MD, PhD
• S. aureus anti-Protein A (SpA) antibody vaccine
and therapeutic: blocks S. aureus SpA surface
protein to promote opsonophagocytic killing,
block immune evasion, and enable protection
against recurrence (adjuvant)
• S. aureus IsdA, IsdB, Coa, ClfA, vWbp antibodies
show protection against S. aureus in a lethal
challenge model
Patrick Wilson, PhD
• Library of fully human pan-neutralizing antibodies
that can effectively target a wide variety of
influenza strains (H1N1, H3, H7, H9 varieties)
• Cell-culture platform for rapid vaccine generation
targeting the H7 flu strain

6. Subunit and Live Vaccines
Superantigens, toxins, immune system
modulators, clotting factors, and proteins
involved in abscess stability all contribute to
severe disease expression during S. aureus
infection. UChicago has assembled a portfolio
of subunit vaccine antigens whose use alone
can limit the disease severity and which in
combination have the potential to prevent or
clear infections.
Combo vaccine prompts protects against severe disease
MRSA
Representative Technologies
Olaf Schneewind, MD, PhD
S. aureus vaccines and therapeutics
• Non-toxigenic Sbi subunit vaccine
• Hybrid Coa subunit vaccine
• EsxD subunit vaccine
• EsaC subunit vaccine
• ClfA/Coa vaccine/ thrombin inhibitor combination
therapy
Y. pestis (Plague) vaccine
• LcrV-based vaccine, in pre-IND authorization
review ahead of a Phase I trial
B. anthracis (Anthrax) vaccine
• PDGA-D4 sortase-conjugated subunit vaccine
based on a component of the anthrax protective
antigen (PA)
Live attenuated S. aureus animal vaccine
• variant S. aureus strain vaccine for the prevention
and treatment of bovine mastitis

7. Platform Technologies
Novel UChicago platforms allow a consistent
approach to be used against a variety of
pathogens and diseases reducing risks and
costs. The potent peptide vaccine adjuvant
platform offers great flexibility whereas the
HMW-PEG-based virulence suppression
platform prevents a range of diseases and
complications associated with surgery or
implants.
Fibrilizing peptide platform enhances antibody response
Representative Technologies
Joel Collier, PhD
• Inducible fibrilizing conjugate peptide adjuvant
that slows clearance and elicits a strong immune
response
• Defined composition and a defined method of
action distinct from alum or lipid-based adjuvants
Benoit Roux, PhD
• Recombinant OmpF porin for the delivery of
penicillin- or carbapenem-derived antibiotics to
Gram-negative bacteria
John Alverdy, MD
• Midway Pharma is developing a HMW-PEG-based
platform for microbiome-mediated disease
associated with gastrointestinal (GI) disorders and
radiotherapy
• Alverdy’s second class of HMW-PEG derivatives
treat microbiome-mediated anastomotic leak
following GI surgery

8. Available Technologies
Resistance-evading small molecule anti-infectives
UCHI 2215
Daum
Antibiotic potentiator of oxacillin sensitivity
UCHI 2153 Topical small molecule ADAM10 inhibitor for the
Bubeck
treatment of toxin-mediated SSTIs (S. aureus, S.
Wardenburg pneumonia)
UCHI 2102
Missiakas
Broad-spectrum Gram-positive antibiotic:
lipoteichoic acid synthase inhibitor
Multiple leads identified. Potency assays
and animal proof of concept studies
underway
Lead optimization in progress
Antimicrob Agents Chemother, 2011
Improved oxacillin treatment outcomes in experimental skin and
lung infection by a methicillin-resistant Staphylococcus aureus
isolate with a vraSR operon deletion.
Nature Medicine, 2011
A Staphylococcus aureus pore-forming toxin subverts the activity of
ADAM10 to cause lethal infection in mice.
PNAS, 2013
Lead optimization in progress
Small molecule inhibitor of lipoteichoic acid synthesis is an
antibiotic for Gram-positive bacteria.
UCHI 2056 Humanized anti-SpA antibody therapeutic vaccine
Schneewind against S. aureus
Commencing GMP manufacturing; efficacy
demonstrated in murine challenge model,
promotes OPK in human blood
Infection and Immunity, 2012
UCHI 2115 Monoclonal antibodies against S. aureus IsdA, IsdB,
Schneewind Coa, ClfA that protect against S. aureus infection
Lead CDRs identified, efficacy demonstrated PLOS Pathogens, 2010
Contribution of coagulases towards Staphylococcus aureus disease
in murine challenge model
and protective immunity.
Antibody-based therapeutics and vaccines
Protein A-specific monoclonal antibodies and prevention of
Staphylococcus aureus disease in mice.
UCHI 2017 A direct thrombin inhibitor in combination with anti- Lead CDRs identified, efficacy demonstrated PLOS Pathogens, 2011
Preventing Staphylococcus aureus sepsis through the inhibition of
in murine challenge model
Schneewind ClfA mAbs protects against S. aureus infection
its agglutination in blood.
TNT-0220
Wilson
Fully human monoclonal pan-influenza vaccine
antibodies against emerging strains of flu
Efficacy demonstrated
PNAS, 2012
Pandemic H1N1 influenza vaccine induces a recall response in
humans that favors broadly cross-reactive memory B cells.
Subunit vaccines
Infection and Immunity, 2012
UCHI 2133 Recombinant subunit S. aureus vaccine antigens
Schneewind (non-toxigenic Sbi, hybrid Coa, EsxD, EsaC)
Efficacy demonstrated in murine challenge
model
UCHI 2055 Sortase-conjugated capsule (PDGA)-protective
Schneewind antigen (D4) B. anthracis (anthrax) vaccine
Vaccine, 2012
Proof of concept efficacy studies completed Sortase-conjugation generates a capsule vaccine that protects
UCHI 1239
LcrV-based Y. pestis (Plague) vaccine
Schneewind
UCHI 1976
McLeod
Peptide vaccine for Toxoplasma gondii
Coagulases as determinants of protective immune responses
against Staphylococcus aureus.
guinea pigs against Bacillus anthracis.
In pre-IND authorization review ahead of a
Phase I trial
Vaccine, 2011
Prevention of pneumonic plague in mice, rats, guinea pigs and nonhuman primates with clinical grade rV10, rV10-2 or F1-V vaccines.
Human Immunology, 2012
Proof of concept efficacy studies completed Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide
with adjuvants and a universal helper T cell epitope elicits…

9. Available Technologies
Live attenuated strain vaccines
UCHI 2137
Live attenuated S. aureus strains
Schneewind
Optimizing the strain genetics
mBio, 2013
Role of Protein A in the Evasion of Host Adaptive Immune
Responses by Staphylococcus aureus.
Platforms: adjuvants, delivery technologies
UCHI 2191
Roux
UCHI 2079
Collier
Recombinant porin as a method of delivering
antibiotics to Gram-negative microbes
Fibrilizing domains act as adjuvants when fused to
small protective epitopes or antigens
UCHI 978
Alverdy
Multicomponent Intestinal Preparation Solution
Designed to Prevent Gut-derived Sepsis
UCHI 2152
Alverdy
High molecular weight PEG derivative s for the
treatment of anastomotic leak
Proof of concept studies underway
Proof of concept studies underway
Initial proof of concept studies completed.
Additional studies and marketing efforts
underway
Structure, 2013
The binding of antibiotics in OmpF porin.
PNAS, 2010
A self-assembling peptide acting as an immune adjuvant.
Am J Physiol Gastrointest Liver Physiol., 2009
Oral PEG 15-20 protects the intestine against radiation: role of lipid
rafts.
PloS One, 2012
Initial proof of concept studies completed.
Intestinal tissues induce an SNP mutation in Pseudomonas
aeruginosa that enhances its virulence: possible role in
anastomotic leak.

10. How to Partner with the University of Chicago
Contact UChicagoTech, the Center for Technology Development & Ventures,
to learn more.
We build strong industry partnerships to successfully bring innovation to the
marketplace. UChicagoTech can connect you to emerging technologies and fieldadvancing researchers that may inform and enrich your own innovation efforts. We
value your involvement at every stage of the invention pipeline, from idea to tangible
asset. For more information, visit us at tech.uchicago.edu or contact anyone on the
Infectious Disease team.
Thomas Jones, PhD
Associate Project Manager
Phone: 773-834-3208
tjones@tech.uchicago.edu
Divya Varshney, MBA
Chief Marketing Officer
Phone: 773-702-8696
dvarshney@tech.uchicago.edu
Glenna Smith, PhD
Project Manager
Phone: 773-702-6122
gsmith@tech.uchicago.edu